Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Riluzole attenuates excitatory amino acid transporter type 3 activity in Xenopus oocytes via protein kinase C inhibition.
Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Tangier's disease: An uncommon cause of facial weakness and non-length dependent demyelinating neuropathy.
Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients
New management algorithms in multiple sclerosis.
Alemtuzumab: The advantages and challenges of a novel therapy in MS.
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
A culture system to study oligodendrocyte myelination processes using engineered nanofibers.
Remyelination: The True Regeneration of the Central Nervous System.
Multiple sclerosis: Five new things.
Pharmacology of HIV integrase inhibitors.
Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Damage to the optic chiasm in myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis mice.
Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran.
[Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate].
Pattern of Uveitis in an Egyptian Population with Multiple Sclerosis: A Hospital-Based Study.
The translational biology of remyelination: Past, present, and future.
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Sphingolipids in ocular inflammation.
Metabolic and safety issues for multiple sclerosis pharmacotherapy - opportunities for personalised medicine.
Mycovirus-like DNA virus sequences from cattle serum and human brain and serum samples from multiple sclerosis patients.
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
[Change of treatment in patients with multiple sclerosis and its consequences in clinical practice].
The nervous system's potential role in multiple sclerosis associated bone loss.

Pages